Hyundai Bio Receives Approval for Additional Administration of ‘Penitrium’ to Patients Who Completed Phase 1 Prostate Cancer Clinical Trials
4 Articles
4 Articles
Hyundai Bio announced on the 17th that the Ministry of Food and Drug Safety has approved the use of the novel anticancer drug candidate ‘Penitrium (CP-PCA07)’ for the first patient participating in the Phase 1 clinical trial for prostate cancer, allowing the drug to continue to be administered even after the trial has concluded. The Phase 1 trial, currently underway at Seoul National University Hospital, involves a patient with metastatic castra…
On the 17th, Hyundai Bioscience (CEO Jin Geun-woo) announced that its novel anticancer drug candidate, ‘Penetrium (CP-PCA07)’, received approval from the Ministry of Food and Drug Safety on the 16th for use for individualized treatment. Regarding the first patient participating in the Phase 1 clinical trial for castration-resistant prostate cancer currently underway at Seoul National University Hospital
[Digital Daily, Reporter Wang Jinhwa] Hyundai Bioscience revealed the initial clinical observation results of 'Penitrium', a new drug candidate being developed for the purpose of overcoming resistance to anticancer drugs. The explanation is that prostate-specific antigen (PSA) levels decreased as a result of concomitant administration of phenytrium to prostate cancer patients who are resistant to existing anticancer drugs. Hyundai Bioscience ann…
The logo of Hyundai Bioscience. [Photo courtesy of Hyundai Bioscience] South Korea’s Hyundai Bioscience announced on Nov. 19 that its experimental cancer drug Penetrium has shown promising results in an early-stage clinical trial involving patients with advanced prostate cancer who had developed resistance to conventional treatments. The Seoul-based biotechnology company noted that observations from an ongoing Phase 1 trial at Seoul National Uni…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium





